Ipamorelin vs Tesamorelin
Both are studied along the growth hormone axis, and both appear in the CJC-1295 + Ipamorelin research pairing lineage — but they act on different receptors and sit at very different points on the clinical-evidence spectrum.
At a Glance
| Ipamorelin | Tesamorelin | |
|---|---|---|
| Category | GHRH & Growth Hormone Peptides | GHRH & Growth Hormone Peptides |
| Molecular class | Pentapeptide (5 amino acids), selective ghrelin-receptor agonist | Stabilized analog of native GHRH(1-44) |
| Discovery timeline | Developed at Novo Nordisk, first published 1998 (Raun et al.) | Developed by Theratechnologies; FDA-approved as Egrifta in 2010 |
| Primary mechanism studied | Ghrelin receptor (GHSR1a) agonism — triggers pulsatile GH release | GHRH receptor agonism — extends and stabilizes the natural GHRH signal |
| Common research focus | GH-axis pulsatility and receptor-selectivity research | Lipid metabolism and visceral fat research |
| Human clinical trial data | None located — data limited to rat and pig pharmacology studies | Phase 3 (412 participants, NEJM 2007); FDA-approved |
| Sold as a blend | Yes — see CJC-1295 + Ipamorelin Blend | Sold standalone only |
How They Differ
Ipamorelin is a selective ghrelin-receptor agonist: it triggers a pulse of GH release the same way the body's own ghrelin signal does, and its research value centers on doing so with minimal cross-reactivity toward cortisol or prolactin pathways — a selectivity problem that plagued earlier-generation secretagogues. See its full discovery history.
Tesamorelin takes the opposite approach: rather than triggering a pulse through a separate receptor, it is a stabilized analog of GHRH(1-44) itself, engineered to resist the rapid enzymatic degradation that limits the native hormone. Its research base is unusually concentrated on one specific outcome — visceral adipose tissue reduction — which is also the basis of its FDA approval as Egrifta for HIV-associated lipodystrophy. See its full discovery history, or how it compares to CJC-1295 and CJC-1295 directly.
Why They're Often Studied Together
Because GHRH-receptor agonism and ghrelin-receptor agonism act on complementary points of the same growth-hormone axis, researchers frequently reference both compounds when comparing mechanism classes — the same rationale behind pairing Ipamorelin with the GHRH analog CJC-1295 in a combined blend, to study pulsatile release patterns from both angles at once.
Ipamorelin vs Tesamorelin questions
Are Ipamorelin and Tesamorelin interchangeable in research?
No. They act on different receptors — Ipamorelin triggers pulsatile GH release through the ghrelin receptor, while Tesamorelin extends and stabilizes the natural GHRH signal through the GHRH receptor. Researchers studying the growth hormone axis often reference both because the two mechanisms are complementary rather than interchangeable.
Has either compound completed human clinical trials?
Tesamorelin has — it is FDA-approved as Egrifta based on Phase 3 trial data. Ipamorelin has not completed a human clinical trial; its published data is limited to rat and pig pharmacology studies.
Does this comparison mean either compound is approved for a particular use?
No. This page compares Ipamorelin and Tesamorelin for educational and research context only. Both are sold strictly for laboratory research use and are not evaluated or approved for human or animal use, except for Tesamorelin's specific FDA approval as the pharmaceutical Egrifta — a different formulation from the research-grade material sold here.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.